Key facts
- Cofactor Genomics’s last known valuation is $41.9M (Dec 2021).
- It has raised $28.7M across 2 recorded rounds; the latest was Early Stage VC ($6.9M) in Dec 2021.
- Notable investors include Y Combinator, Menlo Ventures, DCVC, AME Cloud Ventures, SVB Financial Group (Dallas) — 30 tracked in total.
- Cofactor Genomics has filed 2 Form Ds with the SEC since 2017, most recently Dec 2021 ($6.9M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for Cofactor Genomics
Funding rounds
2 roundsAbout Cofactor Genomics
Developer of a precision diagnostic assay designed to predict immune responses in oncology. The company offers a machine learning-driven platform that analyzes ribonucleic acid (RNA) sequencing data, enabling healthcare providers to better identify patients likely to benefit from immunotherapy.
- Sector
- Healthcare
- HQ
- Saint Louis, MO, United States
- Employees
- 11
- Website
- cofactorgenomics.com/
- Ownership
- Privately Held (backing)
Cofactor Genomics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cofactor Genomics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cofactor Genomics in its N-PORT filings yet. We sweep new filings monthly.